A surveillance study of the current status of reirradiation and patterns of practice by Yamazaki, Hideya et al.
TitleA surveillance study of the current status of reirradiation andpatterns of practice
Author(s)Yamazaki, Hideya; Fushiki, Masato; Mizowaki, Takashi;Kansai Cancer Therapist Group




© The Author 2016. Published by Oxford University Press on
behalf of The Japan Radiation Research Society and Japanese
Society for Radiation Oncology.; This is an Open Access
article distributed under the terms of the Creative Commons
Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction




Journal of Radiation Research, Vol. 58, No. 1, 2017, pp. 71–78
doi: 10.1093/jrr/rrw059
Advance Access Publication: 8 September 2016
A surveillance study of the current status
of reirradiation and patterns of practice
Hideya Yamazaki1*, Masato Fushiki2, Takashi Mizowaki3 and the Kansai
Cancer Therapist Group
1Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku,
Kyoto 602-8566, Japan
2Department of Radiation Oncology, Nagahama City Hospital, Nagahama, Shiga, Japan
3Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
*Corresponding author. Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi
Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. Tel: +81-75-251-5618; Fax: +81-75-251-5840; Email: hideya10@hotmail.com
Received January 5, 2016; Revised March 24, 2016; Accepted May 1, 2016
ABSTRACT
The aim of this study was to survey the current status of reirradiation (Re-RT) and patterns of practice in Japan.
An email questionnaire was sent to Kansai Cancer Therapist Group partner institutions, using questions similar
to those in the Canadian radiation oncologist (RO) survey (2008). A total of 34 ROs from 28 institutions
returned the survey. All 28 institutions experienced Re-RT cases in 2014. However, 26 of the 28 institutions
(93%) reported difﬁculty in obtaining Re-RT case information from their respective databases. Responses from
19 institutions included the number of Re-RT cases; this rose from 183 in the period 2005–2009 (institution
median = 4; 2–12.9) to 562 in the period 2010–2014 (institution median = 26; 2–225). Important considera-
tions for indication of Re-RT were age (65%), performance status (83%), life expectancy (70%), absence of dis-
tant metastases (67%), and interval since previous treatment (73%). Previous total radiation dose (48%),
volume of tissue irradiated (72%), and the biologically equivalent dose (BED; 68.5%) were taken into account
during Re-RT planning. These factors were similar to those considered in the Canadian survey; however, the
present study did not consider age. In eight site-speciﬁc scenarios, barring central nervous system recurrence,
more than 90% of ROs agreed to perform Re-RT, which was higher than the percentage observed in the
Canadian survey. Re-RT cases have increased in number and aroused interest among ROs in this decade of
advanced technology. However, consensus building to establish guidelines for the practice and prospective evalu-
ation of Re-RT is required.
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INTRODUCTION
The advancement of treatment modalities in surgery, chemotherapy
and radiotherapy (RT) has improved survival rate and loco-regional
control at many sites of cancer occurrence. However, in-ﬁeld cancer
recurrence after RT remains an obstacle to cure [1]. Treatment
options for in-ﬁeld cancer recurrence after RT include surgery, sys-
temic chemotherapy, and reirradiation (Re-RT) [2–7]. With the
advancement of modern radiation techniques, Re-RT has become a
promising optional therapy that uses state-of-the-art advanced tech-
nologies, including intensity-modulated radiation therapy (IMRT),
stereotactic RT (SRT), and particle therapy [5–10]. However, there
is little evidence in support of Re-RT therapy; therefore, radiation
oncologists (ROs) should make clinical decisions on their own
experiences, either with palliative or radical intention. In other
words, Re-RT is still in the experimental phase and requires further
exploration. The objective of this study was to survey the present
state of Re-RT and to determine its patterns of practice for in-ﬁeld
cancer recurrence after previous RT. In addition, we compared the
present results with those of the Canadian survey to examine
changes across decades and between countries [11].
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MATERIALS AND METHODS
A survey questionnaire (refer to supplement) was emailed to ROs regis-
tered in the Kansai Cancer Therapist Group directory as of 2015. At
the time of correspondence, all the respondents were actively practicing
in Japan. Part I of the survey questionnaire investigated the following:
the actual number of Re-RT cases in 2014, 2005–2009 and 2010–2014,
both in total and sub-grouped by location. Part II investigated the indi-
cations for Re-RT, Re-RT treatment planning, and eight case scenarios
selected from the most common tumor types (head and neck, chest,
colorectal, genitourinary, gynecologic and gastrointestinal) reported in
the Canadian survey [11]. The completed questionnaires were received
via email. Comparisons were made between patients treated in 2004–
2009 and those treated in 2010–2014, and between the Canadian sur-
vey and the present Japanese survey. This study deﬁned Re-RT as RT
performed after previous RT of 30 Gy/10 fractions (= EQD2 36 Gy,
using α/β = 3, where EQD2 = equivalent 2-Gy fractions) or more.
A biologically equivalent dose (BED) was calculated into EQD2 using
the linear quadratic model: EQD2 = prescription dose × (α/β + dose
per fraction)/(α/β + 2), where α/β = 10 for tumors and 3 for organs
at risk.
Statistical analysis
All statistical analyses were performed using Stat-view 5.0 statistical
software (SAS Institute, Inc., Cary, NC, USA). The percentage
values were analyzed using the χ2 test, and values were compared
using Mann–Whitney U analysis. All analyses used the P < 0.05
level of signiﬁcance.
RESULTS
A total of 34 ROs from 28 institutions returned the survey. All 28
institutions experienced Re-RT cases in 2014. However 26 institu-
tions (93%) had difﬁculty in obtaining individual Re-RT case details
from their respective databases, primarily because there were no
accompanying details, such as ‘second RT course’ or ‘in-ﬁeld cancer
recurrence after initial RT’. Only 19 institutions provided detailed
information for Re-RT cases (Table 1). Of these, 193 Re-RT cases
(institution median = 6; 1–51) occurred in 2014 (Table 1). The
most common Re-RT sites were the brain (n = 55, 28.9%), vertebral
body (n = 30, 15.8%), chest (n = 30, 15.8%), and head or neck
(n = 28, 14.7%) in 2014. These ﬁgures showed a similar distribution
in 2005–2009 (brain = 18%, vertebral body = 19.7%, chest = 24%,
head and neck = 19.7%) and in 2010–2014 (brain = 30%, vertebral
body = 17.4%, chest = 18.3%, head and neck = 15.3%) except those
for the brain (P = 0.037; Table 1). The number of Re-RT cases
increased from 183 in 2005–2009 (institution median = 4; 2–129) to
562 in 2010–2014 (institution median = 26; 2–225). It should be
noted that one new institution was included in 2010–2014 as it
received sophisticated equipment after 2010.
Table 1. Patient numbers treated by reirradiation in responding institutes
2004–2009 (%) 2010–2014 (%) P-value 2014 (%)
(5 years) (5 years) (Single year)
Total number 183 562 193
Brain 33 (18%) 171 (30%) 0.037 55 (28%)
Head and neck 36 (20%) 86 (15%) 28 (15%)
Chest 44 (24%) 103 (18%) 30 (16%)
Abdomen 17 (9%) 41 (7%) 10 (5%)
Pelvis 9 (5%) 23 (4%) 19 (10%)
Bone mets 6 (3%) 25 (4%) 12 (6%)
Vertebrae mets 36 (20%) 98 (17%) 30 (16%)
Other 2 (1%) 15 (3%) 9 (5%)
Table 2. Demographic data for radiation oncologists (ROs)





Experience (years in RO practice) <5 years 7 (21%) 35 (19%) n.s.
5–10 years 8 (24%) 42 (23%)
11–20 years 11 (32%) 69 (38%)
>20 years 8 (24%) 38 (21%)
72 • H. Yamazaki et al.
Respondent demographics and Re-RT eligibility
and exclusion criteria
Of the total respondents, 24% had been in practice for > 20 years,
whereas 21% had been in practice for < 5 years; these respondent
demographics resembled those of the Canadian survey (Table 2)
[11]. Respondents were asked to comment on patient factors that
would inﬂuence their decision to recommend Re-RT. Important fac-
tors included age (65%), performance status (PS) (83%), life





















Age No 12 (35%) 133 (73%) <0.0001
Yes 22 (65%) 35 (19%)
Unc. 0 (0%) 15 (8%)
Performance
status
Yes 25 (83%) 128 (70%) n.s. ECOG 1≥ 1 (4%) 58 (45%) <0.0001
No 6 (20%) 39 (21%) ECOG 2≥ 13 (50%) 51 (40%)
Unc. 0 (0%) 16 (9%) ECOG 3≥ 6 (23%) 13 (10%)
ECOG 4≥ 0 (0%) 6 (5%)
Unc.a 6 (23%) 0 (0%)
Life
expectancy
Yes 21 (70%) 109 (60%) n.s. 1–3 months 2 (8%) 17 (18%) n.s.
No 9 (30%) 59 (32%) 3–6 months 9 (38%) 33 (36%)
Unc.b 1 (4%) 15 (8%) 6–12 months 7 (29%) 20 (22%)
1–2 years 4 (17%) 14 (15%)
≥2 years 1 (4%) 8 (9%)
Unc.c 1 (4%) 8 (9%)
Distant
metastasis
Yesd 22 (67%) 99 (54%) n.s. (0.08)
No 11 (33%) 60 (33%)





Yes 22 (73%) 144 (79%) n.s. 1–3 months 0 (0%) 18 (13%) 0.03
No 8 (27%) 25 (14%) 3–6 months 4 (15%) 43 (30%)
Unc. 1 (4%) 14 (8%) 6–12 months 12 (46%) 36 (25%)
1–2 years 3 (12%) 14 (10%)
≥2 years 0 (0%) 12 (8%)
Unc. 7 (27%) 21 (15%)
Summation of % does not equal 100% because of duplicated answers. ‘Other’ included distance from OAR, patient will. Unc. = uncertain, RO = radiation oncologist,
ECOG = Eastern Cooperative Oncology Group.
aOne RO replied: ECOG 2≥ for curative Re-RT, ECOG 4≥ for palliation.
bOne RO replied: It is case sensitive.
cOne RO replied: >2 months for palliative and >6 months for curative Re-RT.
dSix ROs replied: Yes for curative Re-RT.
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expectancy (70%), absence of distant metastases (67%), and interval
since initial treatment (73%; Tables 2 and 3). Most respondents
believed that patients should have a minimum Eastern Cooperative
Oncology Group (ECOG) PS of 2–3, a minimum life expectancy
of 6–12 months, and an interval of 6 months or more from
initial treatment to be considered for Re-RT (Table 3). These
ﬁgures were similar to those in the Canadian survey, except those
for age, detailed ECOG PS, and time interval since initial therapy.
The Canadian survey reported that age did not inﬂuence the likeli-
hood of an RO prescribing Re-RT (Table 3) [11].
Factors affecting Re-RT treatment planning
Most ROs suggested that factors such as metastatic work-up (69%),
previous total radiation dose (91%) and the BED (68%) were sig-
niﬁcant considerations when deciding the amount of residual nor-
mal tissue tolerance, the Re-RT dose and Re-RT feasibility
(Table 4). Signiﬁcant factors in deciding Re-RT dose were previous
dose (74%), clinical judgment (79%) and BED (79%). Only 16% of
ROs simultaneously used chemotherapy and Re-RT. Similar
respondent attitudes were observed in the present survey and the
Canadian survey.
Responses for site-speciﬁc case scenarios
Responses to the site-speciﬁc questions are summarized in Table 5.
In this study, 94% of ROs recommended Re-RT for central nervous
system cases, as compared with 34% of ROs in the Canadian survey.
Most ROs (18/24 = 75%) recommended SRT, and one recom-
mended stereotactic radiosurgery (SRS) after debulking surgery. In
general, > 60% of ROs recommended Re-RT for every scenario,
which seems to be higher than the percentage observed in the
Canadian survey (34.8–78.8%); however, the opposite trend was
observed for cervical cancer recurrence cases (Table 5). Ninety-six
percent of Canadian ROs recommended Re-RT in recurrent cervical
cancer scenarios, as compared with 82% of Japanese ROs. Japanese
ROs recommended only brachytherapy, whereas Canadian ROs
recommended external beam radiotherapy (EBRT) + BT.
DISCUSSION
The aim of this study was to survey the present state of Re-RT; this
included comparing the attitude towards Re-RT between Japanese
ROs in 2015 and Canadian ROs in 2008. The widely prevailing
notion that Re-RT cannot be used after a radical course of RT con-
tinues to hinder the active management and treatment of patients
with in-ﬁeld cancer recurrence. Factors determining the safe and
effective use of Re-RT include primary tumor site, the initial cancer
stage, type of initial treatment (radiation dose, technique, dose
per fraction, use of concurrent chemotherapy), response to initial
treatments, clinically apparent late effects from initial RT, residual
radiation tolerance of the normal tissues (including BED calcula-
tion), the duration of the relapse-free interval, and the existing
literature. Re-RT purpose (radical or palliative) is also an important
Table 4. Factors affecting reirradiation planning
No. of ROs (%) (%) of Canadian ROs [11]
Metastatic work-up Yes 22 (69%) (72%)
No 4 (13%)
Unc. 6 (19%)
Normal tissue tolerancea Previous dose 31 (91%) (90%)
Clinical decision 21 (62%)
BED 23 (68%) (69%)
Irradiated volume 13 (38%) (90%)
Factor to decide Re-RT dosea Previous dose 25 (74%)
Clinical decision 27 (79%) (83%)
BED 27 (79%) (53%)
Irradiated volume 13 (38%)
Otherb 1 (3%)
Chemotherapy use Yes 5 (16%) (28%)
No 16 (50%)
Unc. 11 (34%)
aSummation of % does not equal 100% because of duplicated answers.
b‘Other’ included distance from organs at risk, patient will. Unc. = uncertain, RO = radiation oncologist.
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Table 5. Attitude to reirradiation for site-speciﬁc case scenarios
Case
No.





Reason for Re-RT decision
(in descending order)
Methods and dose fractionation (in descending order)
Yes No Unc. (%)
‘Yes’
(%) ‘Yes’ RO’s answer Canadian ROs [11]
1 Central nervous
system
30 2 0 (94%) (34.8%) Curative Yes (No other option left) (For QOL
maintenance) (Modern
technology: SRT and IMRT
available) (Young age)
No (Risk of brain necrosis) (Surgery
preferred)
SRT (25–48 Gy/3–8 fr),
IMRT (20–40 Gy/
7–15 fr), SRS, BT
(25–30 Gy/5–10 fr)
SRS (15 Gy or 18 Gy/1 fr),
3D-CRT EBRT (20 Gy/10 fr,
25–40 Gy/20 fr, 30 Gy/5 fra)
2 Head and neck ca.
(nasopharyngeal
cancer)
27 4 0 (87%) (78.8%) Curative Yes (No other option left) (More
effective than chemotherapy)
No (Surgery preferred)
(Chemotherapy preferred) (Risk of
visual disturbance)
IMRT (40–70 Gy/20–35
fr), SBRT (20–40 Gy/
5–10 fr), 3D-CRT, BT
(18–48 Gy/6–12 fr bid)
3D-CRT, IMRT, SRS (18 Gy/
1 fr), BT,EBRT (50–70 Gy/
25–35 fr, 60 Gy/25 fr, 50 Gy/




23 7 2 (72%) (65%) Curative Yes (Useful for palliation more than
CTX) (QOL maintenance;
hemosputum prophylaxis) (Yes for
peripheral lesion, but no for central
lesion) (SBRT, IMRT, Particle
radiotherapy preferred) (Long
interval)
No (Depend on place and recurrent
pattern) (Primary and lymph node
area could be too large to Re-RT)
(Difﬁcult to identify the lesion
from radiation ﬁbrosis) Unc. (Yes




(30 Gy/10 fr, 48–60 Gy/





endobronchial BT (8 Gy/1 fr,
14–15 Gy/ 2–3 fr/ 2–3 weeks),
IMRT EBRT (30 Gy/10–15 fr,
36 Gy/12 fr, 25 Gy/10 fr,
20 Gy/5 fr)
4 Breast ca. 21 11 0 (66%) (51.9%) Curative Yes (Long interval from initial RT)
(Curative potential for oligo
recurrence) (Skin could tolerable)
(No serious OAR involved except







Electron therapy, 2D RT, BT
(50 Gy LDR or 20–25 Gy
HDR/4–5 fr bid/2–2.5 days),
3D-CRT, IMRT EBRT
(30–50 Gy/15–25 r, 30–50 Gy/



















Reason for Re-RT decision
(in descending order)
Methods and dose fractionation (in descending order)
Yes No Unc. (%)
‘Yes’
(%) ‘Yes’ RO’s answer Canadian ROs [11]
No (Hormonal Tx preferred)
(Prophylaxis Re-RT may be
overtreatment) (No symptom)




19 12 0 (61%) Not available Palliative Yes (No other option left) (Small
lesion) (Palliative merit)
(According to patient’s will)
(Brain could be tolerated up to
60 Gy)
No (Too many lesions) (Symptom
could not be related to lesions)
(Multiple small lesions indicated
meningitis carcinomatosa) (Toxicity
concern) (Wait for steroid
refractory)
SBRT (18–25 Gy/1 fr,
30–36 Gy/3 fr), 3D-CRT
(30–40 Gy/5–10 fr),
IMRT (45–60 Gy/15 fr,
35 Gy/5 fr)
Not available
6 Cervical ca. 28 3 3 (82%) (95.5%) Curative Yes (No other option left) (Curative
possibility) (Brachytherapy could
avoid severe toxicity)
No (Surgery preferred) (Toxicity
concern)
BT (HDR 18–25 Gy/
4–5 fr, 36–42 Gy/6–
5 fr), SBRT and IMRT
(20 Gy/5 fr – 48 Gy/
8 fr)
3D-CRT, IMRT, 2D EBRT
followed by BT (40–50 Gy/
20–25 fr/4–5 weeks followed by
BT (LDR) 60–65 Gy) EBRT
alone (45 Gy/25 fr, 40 Gy/20 fr,
30 Gy/20 fr) BT alone
(35–50 Gy LDR/4–6 days or
20–25 Gy HDR/4–5 fr bid/
2–2.5 days)
7 Rectal ca. 22 7 5 (65%) (61.1%) Curative Yes (No other option left) (Particle
therapy preferred) (Palliative merit:
pain relief) (BT possible)
No (Re-RT is not routine protocol)
(Toxicity concern)
IMRT (30–40 Gy/50 fr,
50–66 Gy/20–25 fr,
30 Gy/10 fr), 3D-CRT
(30 Gy/10 fr, 20 Gy/5 fr,
8 Gy/1 fr, 40 Gy/20 fr),
Charged particle, BT
(8 Gy/1 fr, 20–30 Gy,
66 Gy/33 fr; SIB)
3D-CRT, conventional RT, SRS,
IMRT EBRT (30 Gy/10 fr,








determinant, which is inﬂuenced by the presence of distant metasta-
ses (other active lesions), PS and age. Although age and PS were
important factors in Japan, the Canadian survey showed that those
were not limiting factors when deciding whether Re-RT was needed
(Tables 1, 2), possibly reﬂecting the attitudes changing from pallia-
tive to curative intentions with current challenges with using
advanced technology today [11].
Re-RT cases increased in number from 2005–2009 to 2010–2014,
indicating that ROs are becoming more familiar with Re-RT; this was
also true in the comparison between the present survey and the
Canadian survey [11]. This may have been because RT technology
has considerably improved during this decade, and more patients are
receiving Re-RT therapy using state-of-the-art equipment. Re-RT has
been successfully used with acceptable morbidity for a variety of
locally recurrent tumors, including tumors of the breast, head and
neck, brain, pelvis, bone and lung [6]. However, occasionally lethal
side effects such as carotid blow-out syndrome may occur [12]. The
risks of normal tissue complications and the lack of adequate data on
recovery from radiation injury were the common barriers to using
Re-RT as a salvage treatment modality. Acutely responding tissues
fully recover within a few months, and these tissues can tolerate
retreatment as well as untreated tissue [13]. On the other hand, the
pattern of recovery from radiation injury varied considerably in late-
responding tissues. Late-responding tissues (the heart, bladder and
kidney) do not exhibit long-term recovery, whereas the skin, mucosa,
lung, and spinal cord do recover from occult injury of varying magni-
tudes [9]. Several studies have analyzed the suitability of Re-RT for
in-ﬁeld cancer recurrence and reported that Re-RT (with or without
chemotherapy) results in adequate loco-regional tumor and symptom
control [5–7, 14–17].
An additional barrier to the use of Re-RT is the paucity of
data available to determine the Re-RT schedule and dose fractionation–
volume relationships, although hyperfractionated schedules or day-
after-day schedules were suggested as a means of limiting retreatment
toxicity [18, 19]. In addition, newly installed technology (SRT, IMRT,
IGRT, particle therapy and image-guided brachytherapy) increased the
Re-RT potential, which simultaneously made it more difﬁcult to estab-
lish a clear consensus on Re-RT. For example, charged particle therapy
was recommended for several recurrence sites in this survey (Table 5);
this was not observed in the Canadian survey [11]. Recently, newer tech-
nologies, such as 3D conformal radiotherapy (3D-CRT), IMRT, SRS,
SRT and charged particle therapy, have inﬂuenced Re-RT planning and
delivery to facilitate normal tissue tolerance. For example, in this survey
three ROs recommended charged particle radiotherapy for rectal cancer.
The consensus on palliative or curative intention has also been
changing recently; the oligometastasis concept illustrates this [20].
Furthermore, the presently available database systems do not facilitate
the easy retrieval of Re-RT cases. Most institutions reported difﬁculty
in retrieving Re-RT case information. Some institutions examined the
data for all patients that received RT twice or more, to identify the
overlap between initial RT ﬁelds and the Re-RT ﬁeld. An easy system
for Re-RT case information retrieval from databases is essential for the
future exploration of Re-RT utility. Finally, future studies should also
take into account the quality of life for patients who undergo Re-RT.
In conclusion, this decade saw an increase in the number of Re-
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However, further consensus building is required, to establish guide-
lines for practice and prospective evaluation.
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